The Severe Immunotherapy Complications Service at Mass General was created to address the urgent need to understand how and why toxicities occur, in order to develop new therapies that will allow patients to safely stay on their lifesaving immunotherapy regimens.
Departments, Centers, & Programs:
MGH Cancer Center, Bartlett Hall
55 Fruit Street
Boston, MA 02114
- MD, University of Missouri School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Dana Farber Cancer Institute
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
We are in the midst of an exciting revolution in the treatment of cancer. By harnessing and enhancing the body’s immune system using novel therapies such as immune checkpoint inhibitors, we can reduce the amount of tumor burden in patients and, in a subset of patients and cancers, achieve long-lasting remission. However, these therapies are often limited by treatment-induced autoimmune adverse events. They affect nearly every organ system, ranging widely from minor rashes and fevers to severe gastrointestinal, pulmonary, or cardiac complications. Dr. Kerry Reynolds, along with Dr. Chloe Villani, and the Massachusetts General Hospital has taken a lead in this arena by altering our clinical practice model to provide expert multi-disciplinary care by creating the Severe Immunotherapy Complications Service. Importantly, this group is not just involved in the clinical care but they have banded together to set up infrastructure to empower specimen collection and facilitate translational research efforts, in order to understand the mechanisms driving immune-related adverse events (irAEs). Blood/tissue samples are systematically collected in an attempt to develop better therapies to treat autoimmune toxicities while maintaining anti-tumor immunity. The hope is that this will further our understanding of early mechanisms leading to autoimmune diseases and identify novel druggable targets with immunosuppressive potential. The Severe Immunotherapy Complications Service brings together expertise from a variety of clinical divisions and scientists across the institution to coordinate our care and tackle a critical problem facing many cancer patients today.
Sise ME, Seethapathy H, Reynolds KL. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. Oncologist. 2019 24(6):735-742 PMID: 30902916
Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 24(4):435-443.(April, 2019). PMID:30482825.
Reynolds K, Thomas M, Dougan M. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist 23(9):991-997. (2018) PMID: 29853659
Zubiri L, et al, Reynolds KL. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21. PMID: 31754069
Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. Curr Oncol Rep. 2020 Mar 21; 22(4):39. PMID: 32200442.
Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL. Diagnosis and Management of Rare Immune-Related Adverse Events. Oncologist. 2020 01; 25(1):6-14. PMID: 31694890.
Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized Bullous Mucocutaneous Eruption Mimicking Stevens-Johnson Syndrome in the Setting of Immune Checkpoint Inhibition: A Multicenter Case Series. J Am Acad Dermatol. 2020 Mar 18. PMID: 32199891.
- Oct | 21 | 2019
Billy Costa of Kiss 108 Radio sits down with Dr. Kerry Reynolds and Dr. Chloe Villani to learn about the incredible team dynamic between research and clinical practice for patients at the Mass General Cancer Center.
- Apr | 27 | 2020
In this video, Dr. David Ryan chats with Dr. Kerry Reynolds, Clinical Director of the Inpatient Oncology Units at the Cancer Center.
- May | 18 | 2019
Mass General Cancer Center's Dr. Kerry Reynolds discusses the management of toxicities in an inpatient setting. This video was recorded on May 18, 2019 at the Annual Advances in Cancer Immunotherapy CME Course.
- Nov | 15 | 2019
Massachusetts General Hospital in Boston established its immunotherapy toxicity service care team in part because of the experience of David M., a patient treated there for metastatic melanoma that spread to the lung and brain.
- Nov | 5 | 2019
Over the last decade, immunotherapies have increasingly offered hope to thousands of patients with cancer; however, this does not come without its adverse events (AEs), according to Kerry Reynolds, MD.